NEW YORK, May 27, 2026, 11:07 EDT
- Alector was up 3.7% at $2.27 late morning on the Nasdaq, outpacing a 1.2% rise in the XBI biotech ETF.
- Alector is taking action after it halted a GSK-partnered Alzheimer’s trial for futility in late April.
- Investors have to balance Alector’s early-stage brain-delivery work with its cash burn, lack of approved products, and a new $125 million at-the-market stock sale program.
Alector Inc. shares moved higher Wednesday, climbing ahead of other biotech names. Traders came back to the small-cap neuroscience stock a few weeks after a fresh clinical setback shifted the focus to its earlier-stage pipeline.
Shares rose 3.7% to $2.27 late in the morning, opening at $2.20 and hitting a session high at $2.27. The SPDR S&P Biotech ETF, often tracked for small-cap biotech stocks, was up 1.2%.
Alector shares moved without a new company update. The action centers on whether investors back Alector’s shift from failed drug trials to its ABC, or Alector Brain Carrier, platform and think its next pipeline can make a difference.
Alector finished Tuesday down 0.9% at $2.19 and was trading after the Nasdaq opened Wednesday. The shares are still stuck in the low single digits, making the stock move on small shifts in talk about cash, trial pace, or Wall Street notes.
Alector said this month it had $206.5 million in cash, cash equivalents and investments as of March 31, which it expects to last at least through 2027. The company posted a first-quarter net loss of $22.9 million, or 21 cents per share, less than the $40.5 million loss a year ago.
Pipeline questions are sticking around. On April 29, Alector said it would stop the Phase 2 PROGRESS-AD trial of nivisnebart (AL101/GSK4527226) for early Alzheimer’s after a planned futility check showed it likely wouldn’t meet goals. “Disappointing for patients and families,” CEO Arnon Rosenthal said, and pointed to the “complexity” of Alzheimer’s drug development. Alector
GSK and Alector were working together on nivisnebart. The companies’ deal goes back to 2021, when GSK paid Alector $700 million upfront, with the chance for as much as $1.5 billion extra if the drugs hit development, regulatory, and launch milestones.
The company has started to count more on ABC, its blood-brain barrier platform. The platform is built to get therapies into the brain, past the blood-brain barrier that blocks many drugs and other substances. In the company’s quarterly update, Rosenthal said Alector has made a “highly differentiated” platform for getting antibodies, enzymes, proteins and siRNA, a gene-silencing technology, into brain tissue. GlobeNewswire
Morgan Stanley’s Sean Laaman bumped up Alector’s price target to $2 from 90 cents but stuck with an Underweight call. Laaman said the failure of AL101 acts as a “clearing event” and may free up $30 million to $50 million every year for ABC programs’ R&D. Analysts are split—lower short-term risk but the story is still unproven. Investing
Alzheimer’s drug makers face tough competition. Biogen and Eisai’s Leqembi was the first amyloid beta antibody to get traditional U.S. approval. Eli Lilly’s Kisunla won approval for early Alzheimer’s in 2024. Both focus on amyloid, the protein that often builds up in Alzheimer’s patients’ brains.
Alector’s coming pipeline is still in early stages. The company has named AL037/AL137, an ABC-enabled anti-amyloid beta program, plus preclinical projects in Parkinson’s and tau-linked disorders. An IND, or investigational new drug application, is needed before human tests start in the U.S.
The trade isn’t without risk. In its latest quarterly filing, Alector said it has no approved products, no product revenue and “no active clinical trials.” The company warned that drug development is uncertain. Alector also said it will need a lot more financing down the line, and any equity raise would dilute existing shareholders by boosting the share count. Alector
Alector set up an at-the-market program on May 7 to sell as much as $125 million in common stock through TD Cowen. The company said there’s no obligation to sell shares and any funds raised would go to general corporate uses, such as research, development, and manufacturing.
Wednesday’s action is shaping up as more of a tweak to expectations than a firm call. The bigger question now is if ABC gets past preclinical promise and delivers human data, and if it can do that without new delays or big costs.
